Perspective Therapeutics (CATX) vs Mobia Medical (MOBI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Perspective Therapeutics is the larger company by market cap ($309.9 million vs $285.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CATX | MOBI |
|---|---|---|
| Share price | $2.72 | $8.56 |
| Market cap | $309.92M | $284.97M |
| 1-day change | +10.37% | +0.59% |
| YTD return | -10.55% | — |
| 1-year return | -29.11% | — |
| 5-year return | -60.32% | — |
| EPS (TTM) | $-1.33 | $-2.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.16 | $15.29 |
| 52-week low | $1.96 | $8.30 |
| Distance from 52-week high | -55.93% | -44.02% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +352.67% | +107.36% |
| Average volume | 1.67M | 180.23K |
| Shares outstanding | 114.15M | 33.29M |
| Employees | 163 | 167 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Perspective Therapeutics
CATX stock →Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha.
Health Care · Biotechnology: Pharmaceutical Preparations · 163 employees
About Mobia Medical
MOBI stock →Mobia Medical, Inc. develops and commercializes neurostimulation medical devices, including implantable systems for stroke rehabilitation and other neurological conditions.
Health Care · Medical/Dental Instruments · 167 employees
CATX vs MOBI FAQ
Which is bigger, Perspective Therapeutics or Mobia Medical?
Perspective Therapeutics (CATX) is larger, with a market capitalization of $309.92M compared with $284.97M for Mobia Medical (MOBI).
Are Perspective Therapeutics and Mobia Medical in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Perspective Therapeutics and Medical/Dental Instruments for Mobia Medical.